Pancreatic Cancer
If it’s your first time on this website, please read the disclaimer section.
Jul 20 – Jul 27, 2026
Safety and efficacy of fecal microbiota transplantation in solid cancers resistant to immune checkpoint inhibitors: results of the MITRIC trial.
J IMMUNOTHER CANCER · Q1 JOURNAL - RANK #12/183TOP-TIER
This single-arm phase IIa basket trial (MITRIC; NCT05286294) tested the safety, feasibility, and efficacy of fecal microbiota transplantation (FMT) from immune checkpoint inhibitor (ICI) responders to patients with advanced cancers refractory to ICIs. Patients received up to five FMT administrations in combination with ICIs, with FMT-related adverse events and objective response as co-primary endpoints. Among 12 participants with various solid tumors, no objective responses were observed, five achieved stable disease, and median progression-free survival and overall survival were 1.5 and 10.1 months, respectively. Although FMT plus ICIs proved safe and feasible, clinical activity was limited, highlighting the need for further studies.
10.1136/jitc-2026-015122
Jul 13 – Jul 20, 2026
Adjuvant Chemotherapy ± Chemoradiotherapy for Adenocarcinoma of the Pancreatic Head: Results of the Radiotherapy Random Assignment of NRG Oncology/RTOG 0848.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This multicenter, randomized phase III clinical trial evaluated whether adding fluoropyrimidine-sensitized radiotherapy (CXRT) to adjuvant chemotherapy after curative resection for pancreatic head adenocarcinoma improves overall survival (OS). In step 2, 354 patients were randomized to chemotherapy alone (n=174) or chemotherapy plus CXRT (n=180) after initial chemotherapy. Median OS was 2.6 years for chemotherapy and 2.3 years for chemotherapy + CXRT, with 5-year OS rates of 23.1% and 27.9%, respectively; the primary OS endpoint was not met (HR, 0.96; 90% CI, 0.79–1.18). CXRT increased grade 3 toxicity (38% vs 19%, p<.001), but improved OS and DFS in node-negative patients (p=.0063 and p=.014, respectively).
10.1200/JCO-25-02520
Jun 29 – Jul 06, 2026
Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.
BRIT J CANCER · Q1 JOURNAL - RANK #47/326
This Phase IIa prospective, single-arm trial assessed foslinanib (CVM-1118), an oral anti–vasculogenic mimicry agent, in advanced well‑differentiated NETs refractory/intolerant to prior therapy. Patients (N=43; 35 efficacy‑evaluable) with grade 1–2 lung, gastrointestinal, or pancreatic NETs received CVM‑1118 200–300 mg twice daily in 28‑day cycles; primary endpoint was PFS, with ORR, DCR, OS, and safety secondary. Median PFS was 10.5 months (95% CI 5.6–22.3), ORR 3%, DCR 77%, and median OS not reached (95% CI 23.8–NR); in the full analysis set (N=43), median PFS was 8.4 months, and among those with prior everolimus, sunitinib, or PRRT (N=22), median PFS was 8.3 months. Treatment‑related AEs occurred in 44%, mostly grade 1–2, with no serious events, supporting favorable efficacy and tolerability.
10.1038/s41416-026-03515-w
Neoadjuvant Chemotherapy (FOLFIRINOX or Gemcitabine With Nab-Paclitaxel) for Borderline-Resectable Pancreatic Cancer: Long-Term Results of a Randomized Controlled Trial (NUPAT-01).
J HEPATO-BIL-PAN SCI · Q1 JOURNAL - RANK #59/312
This multicenter phase II randomized controlled trial (NUPAT-01) compared two neoadjuvant chemotherapy regimens—FOLFIRINOX versus gemcitabine + nab-paclitaxel—in 51 patients with borderline-resectable pancreatic cancer, followed by surgery when feasible. Patients were randomized (FOLFIRINOX n=26; GEM/nab-PTX n=25); 43 underwent resection, achieving an R0 margin in 33 cases. Intention-to-treat analysis showed a 3-year overall survival of 51.0 %, a 5-year overall survival of 35.3 %, and a median survival time of 36.5 months, with no statistically significant survival difference between regimens. The authors conclude that both multidrug regimens are feasible and produce comparable long-term outcomes, while individual survival is more strongly linked to chemotherapy response than to specific regimen choice.
10.1002/jhbp.70150
Jun 22 – Jun 29, 2026
Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study.
CLIN CANCER RES · Q1 JOURNAL - RANK #29/326TOP-TIER
In a randomized, open-label, phase II trial, patients with treatment-naïve metastatic pancreatic ductal adenocarcinoma received NIS793 (± spartalizumab) combined with nab-paclitaxel/gemcitabine (ABRA/GEM) or ABRA/GEM alone to assess progression-free survival. Key endpoints included overall survival, safety, pharmacokinetics, and biomarker analyses, with paired tumor RNA sequencing, cfDNA profiling, and plasma proteomics as exploratory measures. Targeting TGFβ with NIS793 demonstrated effective TGFβ suppression and stromal remodeling, evidenced by downregulation of CAF markers (ACTA2, FAP) and collagen-related signatures. Despite these biological effects, the NIS793 arm showed comparable or numerically worse survival outcomes (HR for OS: 1.32; 95% CI: 0.84–2.07), highlighting the complexity of TGFβ biology in PDAC.
10.1158/1078-0432.CCR-26-0805
Non-thermal focused ultrasound with FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer: An explorative phase II trial.
EUR J CANCER · Q1 JOURNAL - RANK #45/326
This exploratory phase II trial evaluated the safety and efficacy of non-thermal focused ultrasound (FUS) combined with FOLFIRINOX chemotherapy in 60 patients with borderline resectable or locally advanced pancreatic cancer (BRPC/LAPC). The study compared outcomes between 56 patients receiving FUS plus FOLFIRINOX and a propensity score-matched historical cohort of 56 patients treated with FOLFIRINOX alone, assessing objective response rate (ORR), overall survival (OS), progression-free survival (PFS), and toxicity. The FUS group showed significantly higher ORR (64.3% vs. 35.7%; P=0.003), longer OS (24.0 vs. 17.0 months; HR=0.63, P=0.029), and PFS (16.0 vs. 11.0 months; HR=0.65, P=0.039) without increased toxicity (Grade ≥3: 55.4% vs. 57.1%, P=0.849). The findings suggest FUS enhances FOLFIRINOX efficacy in BRPC/LAPC, warranting further phase III investigation.
10.1016/j.ejca.2026.116903
Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study.
SIGNAL TRANSDUCT TAR · Q1 JOURNAL - RANK #1/319TOP-TIER
This multicenter, open-label, single-arm phase 2 trial evaluated nab-paclitaxel plus S-1 as first-line induction therapy for previously untreated locally advanced pancreatic cancer across four centers in China (NCT03885219). Sixty patients received up to eight cycles; the primary endpoint was 6-month progression-free survival (PFS). Results: 6-month PFS was 71.0% (95% CI 57.6–80.9), median PFS 11.1 months, median overall survival (OS) 20.2 months, 12-month OS 83.3%, objective response rate 26.7%, disease control rate 90.0%; 48.3% completed induction, 18.3% underwent resection (10 R0/R1). Grade ≥3 treatment-related adverse events occurred in 53.3% (mainly neutropenia/leukopenia) with no treatment-related deaths; the regimen showed promising activity and potential for conversion to resection.
10.1038/s41392-026-02741-1
Jun 15 – Jun 22, 2026
Nimotuzumab combined with gemcitabine and nab-paclitaxel as first-line therapy for advanced pancreatic cancer: a single-arm, single-center Phase II prospective study.
FRONT MED-LAUSANNE · Q1 JOURNAL - RANK #61/332
This single-arm, single-center Phase II prospective study evaluated the efficacy and safety of a combination regimen (nimotuzumab, gemcitabine, nab-paclitaxel) as first-line therapy for patients with Stage III-IV pancreatic cancer. Sixteen patients (ECOG PS 0-1, no prior systemic chemotherapy) received the NTZ-AG regimen every 21 days for up to six cycles. Results showed an objective response rate (ORR) of 68.75% (11/16, 95% CI: 42.81-87.34), a disease control rate (DCR) of 100%, median progression-free survival (PFS) of 6.0 months, and median overall survival (OS) of 12.0 months. The study concluded that NTZ-AG demonstrated meaningful anti-tumor activity and manageable safety, supporting further exploration in larger clinical trials.
10.3389/fmed.2026.1838482
Jun 08 – Jun 15, 2026
Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO.
JCO PRECIS ONCOL · Q1 JOURNAL - RANK #57/326
The MEKiAUTO phase I trial investigated combined MEK and autophagy inhibition, with or without atezolizumab, in 14 patients with metastatic PDAC using a time-to-event continual reassessment design. Tumor response was measured via advanced molecular assays, with four dose-limiting toxicities observed. Median progression-free survival was 7.7 weeks (95% CI, 6–15.6), and median overall survival was 20.7 weeks (95% CI, 15.6–46.1). While preclinical models showed robust tumor suppression, clinical tolerability and efficacy were limited, attributed to differences in tumor heterogeneity.
10.1200/PO-26-00138
Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61-FUNGEMAX trial (France).
ECLINICALMEDICINE · Q1 JOURNAL - RANK #11/332
This open-label, multicentre, randomized phase II trial enrolled 288 chemotherapy-naïve adults with ECOG 0–1 metastatic pancreatic ductal adenocarcinoma to receive nal-IRI/leucovorin/5-FU (NAPOLI), gemcitabine/nab-paclitaxel (MPACT), or sequential alternation of both every two months. The primary endpoint, 6-month progression-free survival (PFS), was 51.6 % for the sequential arm, 32.3 % for NAPOLI, and 45.3 % for MPACT; neither sequential (HR 0.76, p = 0.072) nor NAPOLI (HR 1.20, p = 0.22) significantly improved PFS versus MPACT. Twelve-month PFS rates were 20.3 %, 12.7 %, and 11.9 %, while 24-month overall survival (OS) rates were 23.8 %, 9.5 %, and 12.5 % for sequential, NAPOLI, and MPACT, respectively. Investigators concluded that the sequential regimen is feasible and tolerable with numerically higher longer-term PFS and OS, warranting larger biomarker-integrated trials against current standards.
10.1016/j.eclinm.2026.103998
Jun 01 – Jun 08, 2026
Daraxonrasib Doubles OS for PDAC in Phase III Trial.
CANCER DISCOV · Q1 JOURNAL - RANK #10/326TOP-TIER
This phase III prospective clinical trial evaluated the pan-RAS inhibitor daraxonrasib versus standard chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma who had progressed after first-line therapy. Patients were randomized to receive daraxonrasib or physician-choice chemotherapy, and overall survival (OS) was the primary endpoint. Daraxonrasib doubled median OS compared with chemotherapy, establishing a new benchmark for second-line treatment; exact numerical values were not provided in the abstract. Investigators concluded that daraxonrasib significantly prolongs survival and supports its adoption as a new standard of care while encouraging additional studies of RAS-targeted therapy.
10.1158/2159-8290.CD-NW2026-0062
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.
NEW ENGL J MED · Q1 JOURNAL - RANK #2/332TOP-TIER
This phase 3, international, open-label randomized trial evaluated daraxonrasib versus chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). A total of 500 participants were randomized, with 91.8% harboring G12 mutations, to receive either daraxonrasib or chemotherapy. Daraxonrasib significantly improved median overall survival (13.2 months vs. 6.6 months in the G12 population, HR: 0.40, P<0.001) and progression-free survival (7.3 months vs. 3.5 months in the G12 population, HR: 0.45, P<0.001). Adverse events occurred in all patients in the daraxonrasib group and 97.7% of the chemotherapy group, with fewer treatment-related discontinuations in the daraxonrasib group (1.2%) compared to the chemotherapy group (11.2%).
10.1056/NEJMoa2605555
May 25 – Jun 01, 2026
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial.
NAT CANCER · Q1 JOURNAL - RANK #11/326TOP-TIER
This randomized, multiarm, run-in phase trial evaluated the safety and pharmacodynamic effects of adding the VDR agonist paricalcitol to gemcitabine and nab-paclitaxel (GA) in 36 patients with metastatic pancreatic cancer. Patients were randomized to GA plus placebo, GA plus intravenous paricalcitol, or GA plus oral paricalcitol, with pretreatment and on-treatment tumor biopsies analyzed. Paricalcitol was safely administered, though 42% of oral paricalcitol recipients experienced grade 2-4 hypercalcemia requiring dose reduction. On-treatment biopsies showed decreased αSMA+ fibroblasts, altered fibroblast VDR activation, increased CD8+ T cell density and spatial colocalization with tumor cells, and VDR expression predicted tumor response in paricalcitol arms.
10.1038/s43018-026-01165-8